How to buy Lineage Cell Therapeutics stock (LCTX)

Lineage Cell Therapeutics is a biotechnology business based in the US. Lineage Cell Therapeutics shares (LCTX) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $0.51 – a decrease of 9.5% over the previous week. Lineage Cell Therapeutics employs 68 staff and has a trailing 12-month revenue of around $6.2 million.

Our top picks for where to buy Lineage Cell Therapeutics stock

Buy Lineage Cell Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Lineage Cell Therapeutics stock price (NYSE MKT: LCTX)

Use our graph to track the performance of LCTX stocks over time.

Lineage Cell Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$0.51
52-week range	$0.48 - $1.61
50-day moving average more info button	$0.72
200-day moving average more info button	$0.95
Wall St. target price	$4.83
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.10

Is it a good time to buy Lineage Cell Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lineage Cell Therapeutics price performance over time

Historical closes compared with the close of $0.505 from 2024-12-26

1 week (2024-12-20)	-9.50%
1 month (2024-11-27)	-11.22%
3 months (2024-09-27)	-45.11%
6 months (2024-06-27)	-50.97%

1 year (2023-12-27)	-57.20%
2 years (2022-12-27)	-51.90%
3 years (2021-12-27)	2.61
5 years (2019-12-27)	0.77

Lineage Cell Therapeutics financials

Revenue TTM	$6.2 million
Gross profit TTM	$14 million
Return on assets TTM	-12.86%
Return on equity TTM	-35.04%
Profit margin	0%
Book value	$0.36
Market Capitalization more info button	$118.6 million

TTM: trailing 12 months

Lineage Cell Therapeutics share dividends

We're not expecting Lineage Cell Therapeutics to pay a dividend over the next 12 months.

Have Lineage Cell Therapeutics's shares ever split?

Lineage Cell Therapeutics's shares were split on a 3:1 basis on 30 October 1997 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Lineage Cell Therapeutics shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Lineage Cell Therapeutics shares which in turn could have impacted Lineage Cell Therapeutics's share price.

Lineage Cell Therapeutics share price volatility

Over the last 12 months, Lineage Cell Therapeutics's shares have ranged in value from as little as $0.481 up to $1.61. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Lineage Cell Therapeutics's is 1.282. This would suggest that Lineage Cell Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Lineage Cell Therapeutics overview

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc.

Frequently asked questions

What percentage of Lineage Cell Therapeutics is owned by insiders or institutions?
Currently 0.441% of Lineage Cell Therapeutics shares are held by insiders and 50.564% by institutions. How many people work for Lineage Cell Therapeutics?
Latest data suggests 68 work at Lineage Cell Therapeutics. When does the fiscal year end for Lineage Cell Therapeutics?
Lineage Cell Therapeutics's fiscal year ends in December. Where is Lineage Cell Therapeutics based?
Lineage Cell Therapeutics's address is: 2173 Salk Avenue, Carlsbad, CA, United States, 92008 What is Lineage Cell Therapeutics's ISIN number?
Lineage Cell Therapeutics's international securities identification number is: US53566P1093 What is Lineage Cell Therapeutics's CUSIP number?
Lineage Cell Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09066L170